Category: Hemophilia

Sangamo Therapeutics shares decline as Pfizer terminates hemophilia gene therapy agreement on monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for the treatment of severe-to-moderate hemophilia A that it co-developed and licensed. Pfizer (NYSE: PFE). Pfizer has…